# Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer

> **NCT00416793** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 9 (actual)

## Conditions studied

- Acinar Cell Adenocarcinoma of the Pancreas
- Duct Cell Adenocarcinoma of the Pancreas
- Stage IV Pancreatic Cancer

## Interventions

- **DRUG:** bortezomib
- **DRUG:** carboplatin
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00416793
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-12
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Study was terminated due to poor accrual
- **Last updated:** 2019-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00416793

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00416793, "Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00416793. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*